Nls Pharmaceutics Ltd (NLSP)

$1.50 0.00 (N/A)
Market Cap 5.40M
Revenue (ttm) 0.00
Net Income (ttm) -12.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.16
Volume 11,500
Avg Vol 88,942
Day's Range N/A - N/A
Shares Out 3.60M
Stochastic %K 56%
Beta -0.21
Analysts Strong Buy
Price Target $4.00

Latest News on NLSP

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

Apr 15, 2025, 9:00 AM EDT - 12 days ago

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

Mar 31, 2025, 9:10 AM EDT - 27 days ago

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

NLS Pharmaceutics CEO Issues Letter to Shareholders

Mar 10, 2025, 7:00 AM EDT - 7 weeks ago

NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

Feb 27, 2025, 7:00 AM EST - 2 months ago

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

Feb 25, 2025, 9:05 AM EST - 2 months ago

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

Feb 10, 2025, 7:30 AM EST - 2 months ago

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

Jan 31, 2025, 7:30 AM EST - 3 months ago

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting

Jan 30, 2025, 7:30 AM EST - 3 months ago

NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

Jan 28, 2025, 7:30 AM EST - 3 months ago

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

Jan 16, 2025, 9:32 AM EST - 3 months ago

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

NLS Pharmaceutics Ltd. and Kadimastem Ltd.

Jan 8, 2025, 7:42 AM EST - 3 months ago

NLS Pharmaceutics Ltd. and Kadimastem Ltd.

NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment

Dec 19, 2024, 7:30 AM EST - 4 months ago

NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment

NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market

Dec 4, 2024, 1:15 PM EST - 5 months ago

NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market

NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders

Dec 3, 2024, 7:40 AM EST - 5 months ago

NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders

Nov 18, 2024, 7:30 AM EST - 5 months ago

NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

Nov 4, 2024, 7:00 AM EST - 6 months ago

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements

Oct 28, 2024, 7:00 AM EDT - 6 months ago

NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence

Oct 21, 2024, 7:00 AM EDT - 6 months ago

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence

NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules

Oct 15, 2024, 7:00 AM EDT - 6 months ago

NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules

NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split

Sep 25, 2024, 8:00 AM EDT - 7 months ago

NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split

Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump

Jul 29, 2024, 12:03 PM EDT - 9 months ago

Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump

NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge

Jul 29, 2024, 7:00 AM EDT - 9 months ago

NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge

NLS Pharmaceutics Announces Registered Direct Offering

Jun 28, 2024, 9:00 AM EDT - 10 months ago

NLS Pharmaceutics Announces Registered Direct Offering

NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments

Jun 27, 2024, 8:00 AM EDT - 10 months ago

NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments

Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements

Jun 25, 2024, 8:30 AM EDT - 10 months ago

Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements

NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)

Jun 11, 2024, 8:30 AM EDT - 11 months ago

NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)

NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing

Apr 19, 2024, 5:00 PM EDT - 1 year ago

NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing

NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering

Mar 22, 2024, 4:30 PM EDT - 1 year ago

NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering

NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering

Mar 20, 2024, 1:40 PM EDT - 1 year ago

NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering

NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform

Mar 20, 2024, 7:30 AM EDT - 1 year ago

NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform

NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event

Mar 14, 2024, 8:00 AM EDT - 1 year ago

NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event

Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance

NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq

Feb 23, 2024, 7:30 AM EST - 1 year ago

NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq

Notice of Deficiency with Nasdaq Continued Listing Requirements

Jan 12, 2024, 4:30 PM EST - 1 year ago

Notice of Deficiency with Nasdaq Continued Listing Requirements

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.

Dec 1, 2023, 7:30 AM EST - 1 year ago

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.

NLS Pharmaceutics Announces Election of Additional Board Members

Nov 28, 2023, 7:30 AM EST - 1 year ago

NLS Pharmaceutics Announces Election of Additional Board Members

NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia

Nov 27, 2023, 8:30 AM EST - 1 year ago

NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia

NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan

Nov 16, 2023, 8:00 AM EST - 1 year ago

NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan

NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Oct 25, 2023, 4:30 PM EDT - 1 year ago

NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions

Oct 19, 2023, 5:00 PM EDT - 1 year ago

NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions

NLS Pharmaceutics Announces Company Update on Strategic Partnerships

Oct 12, 2023, 9:40 AM EDT - 1 year ago

NLS Pharmaceutics Announces Company Update on Strategic Partnerships

NLS Pharmaceutics shares rise as narcolepsy treatment moves to phase 3 studies

Jul 3, 2023, 8:53 AM EDT - 1 year ago

NLS Pharmaceutics shares rise as narcolepsy treatment moves to phase 3 studies

NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol

Jul 3, 2023, 7:00 AM EDT - 1 year ago

NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol

NLS Pharmaceutics Releases the Results from its Annual General Meeting

Jun 30, 2023, 4:05 PM EDT - 1 year ago

NLS Pharmaceutics Releases the Results from its Annual General Meeting

NLS Pharmaceutics Company Update and Webcast Today Postponed

Jun 30, 2023, 8:00 AM EDT - 1 year ago

NLS Pharmaceutics Company Update and Webcast Today Postponed

CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Jun 19, 2023, 7:30 AM EDT - 2 years ago

CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

NLS Pharmaceutics Announces Company Update Webcast

Jun 19, 2023, 7:10 AM EDT - 2 years ago

NLS Pharmaceutics Announces Company Update Webcast

NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Jun 15, 2023, 8:30 AM EDT - 2 years ago

NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol

Jun 14, 2023, 7:30 AM EDT - 2 years ago

NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol

NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer

May 8, 2023, 8:30 AM EDT - 2 years ago

NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer